Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Leiomyosarcoma × berzosertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 6 Ovarian Neoplasms 3 Lung Neoplasms 3 Neoplasm Metastasis 2 Hereditary Sensory and Autonomic Neuropathies 2 Fallopian Tube Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Uterine Cervical Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neoplasms 1 Metastatic Bladder Urothelial Carcinoma 1 Leiomyosarcoma 1 Colorectal Neoplasms 1 Carcinoma, Neuroendocrine 1 Brain Neoplasms 1 Advanced Solid Tumor 1

Interventions

Doxorubicin 20 Gemcitabine 15 Trabectedin 11 Ifosfamide 10 Docetaxel 10 Radiotherapy 8 Dacarbazine 7 pazopanib 6 Temozolomide 4 Biopsy 4 Sunitinib 3 Specimen Handling 3 Sorafenib 3 Nivolumab 3 Filgrastim 3 pembrolizumab 2 pegfilgrastim 2 liposomal doxorubicin 2 eribulin 2 cixutumumab 2 brostallicin 2 belinostat 2 avelumab 2 Surgical Procedures, Operative 2 Radiotherapy, Conformal 2 Radiation 2 PTC596 2 Letrozole 2 Epirubicin 2 Bevacizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03718091 2023-07-07

M6620 (VX-970) in Selected Solid Tumors

Massachusetts General Hospital

Phase 2 Completed

30 enrolled 15 charts

Leiomyosarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡